How many employees work at Nucleome Therapeutics?
Nucleome Therapeutics Ltd. has approximately 49 total employees worldwide as of March 2026, according to Revelio Labs workforce intelligence data. Nucleome Therapeutics’s total headcount has grown 22.6% from 40 employees in 2023 to 49 in 2026.
Is Nucleome Therapeutics hiring right now?
No, Nucleome Therapeutics is not actively hiring. Nucleome Therapeutics had 0 active job postings in 2026, a 0.0% no change from 2025 — see job openings & hiring trends.
About Nucleome Therapeutics’s Workforce
Nucleome Therapeutics Ltd. is a Biotech and Healthcare Services company that employs 49 people worldwide as of March 2026. It is the 6th-largest by headcount among its peers. Founded in 2019, the company is headquartered in Oxford, United Kingdom.
Nucleome Therapeutics's workforce has grown 22.6% from 2023 to 2026, though it is down 12.7% year over year in 2026. It fell to a low of 39 in 2023 Q3 before recovering. Its workforce is concentrated most in Northern Europe (100.0%).
Nucleome Therapeutics's functional groups are Engineering (45.1%), Finance and Operations (32.5%), and Sales and Marketing (22.4%), with Engineering growing fastest (up 12.1%). The average salary is $123,700, highest in Northern Europe at a median of $108,000, up 23.0% year over year in 2026.
Nucleome Therapeutics's hiring activity held steady in 2026.
Sourced from Revelio Labs workforce data.
- Headquarters
- Oxford, United Kingdom
- Founded
- 2019
- Industry
- Biotech and Healthcare Services
- Employees
- 49
- YoY
- -12.7% (-6)
As of March 2026
Nucleome Therapeutics workforce metrics
Unlock hiring rate, attrition rate, and 12 additional workforce metrics for Nucleome Therapeutics. Compare to peers, export the dataset, and access the full quarterly history.
Unlock MetricsNucleome Therapeutics Annual Employee Count (2023-2026)
- Nucleome Therapeutics had 49 employees in 2026, a 12.7% decline (-6) from 2025.
- Nucleome Therapeutics had 50 employees in 2025, a 21.7% decline (-7) from 2024.
- Nucleome Therapeutics had 57 employees in 2024, a 1.8% increase (+13) from 2023.
- Nucleome Therapeutics had 44 employees in 2023, a 6.8% increase (+17) from 2022.
Nucleome Therapeutics's total workforce has grown from 40 employees in 2023 to 49 in 2026.
Nucleome Therapeutics Ltd. quarterly employee count
| Year | Qtr | Employees | YoY Change | YoY % |
|---|---|---|---|---|
| 2026 | Q1 | 49 | -6 | -12.7% |
| 2025 | Q4 | 50 | -7 | -21.7% |
| 2025 | Q3 | 52 | -3 | -16.7% |
| 2025 | Q2 | 54 | +2 | -17.2% |
| 2025 | Q1 | 55 | +5 | -10.2% |
| 2024 | Q4 | 57 | +13 | +1.8% |
| 2024 | Q3 | 55 | +16 | +1.3% |
| 2024 | Q2 | 52 | +12 | +1.2% |
| 2024 | Q1 | 50 | +18 | +5.4% |
| 2023 | Q4 | 44 | +17 | +6.8% |
| 2023 | Q3 | 39 | +11 | -0.6% |
| 2023 | Q2 | 40 | +17 | +12.4% |
See Nucleome Therapeutics's complete headcount history, including quarterly breakdowns.
Get the DataNucleome Therapeutics Employee Count by Region (2026)
Northern Europe accounts for the largest share of Nucleome Therapeutics's global workforce with approximately 100% of total employees.
Nucleome Therapeutics employees by region
| Region | Employees | % of Total |
|---|---|---|
| Northern Europe | 48 | 100.0% |
Drill into city-level data, hiring trends by region, and historic geographic shifts.
Unlock Geographic DataNucleome Therapeutics Employee Count by Department (2026)
Nucleome Therapeutics's employee groups are Engineering (45.1%), Finance and Operations (32.5%), and Sales and Marketing (22.4%).
Nucleome Therapeutics employees by department
| Department | Employees | % of Total |
|---|---|---|
| Engineering | 22 | 45.1% |
| Finance and Operations | 16 | 32.5% |
| Sales and Marketing | 11 | 22.4% |
Compare Nucleome Therapeutics's department mix to industry peers.
See Full DataNucleome Therapeutics Employee Salary by Region (2026)
Nucleome Therapeutics's average employee salary is $123,700 globally. Employees in Northern Europe receive the highest compensation.
Nucleome Therapeutics median employee salary by region (USD)
| Region | Median Salary |
|---|---|
| Northern Europe | $108,000 |
Unlock salary by role, level, and city — and compare to Nucleome Therapeutics's industry peers.
Unlock Salary DataNucleome Therapeutics Job Openings and Hiring Trends (2023-2026)
- Nucleome Therapeutics had 0 active job postings in 2026, a 0% no change from 2025.
- Nucleome Therapeutics had 0 active job postings in 2025, a 200.0% decline (-3) from 2024.
- Nucleome Therapeutics had 3 active job postings in 2024, a 200.0% increase (+3) from 2023.
- Nucleome Therapeutics had 0 active job postings in 2023, a 200.0% decline from 2022.
- Hiring velocity in 2026: 0 new roles/month, up from 0 in 2025 and 1 in 2024.
Nucleome Therapeutics's hiring activity held steady in 2026.
Track new postings per month, role-level demand, and hiring velocity vs. peers.
Unlock Hiring DataSimilar Companies
Similar Biotech and Healthcare Services Companies by Employee Count
Frequently Asked Questions About Nucleome Therapeutics
- How fast is Nucleome Therapeutics growing?
- In 2026, Nucleome Therapeutics's headcount shrank 12.7% to 49 employees, down from 55 in 2025.
- See the full headcount history
- Where are Nucleome Therapeutics employees located?
- Most Nucleome Therapeutics employees are based in Northern Europe (100.0% of headcount).
- Explore where the workforce is based
- What is the average salary at Nucleome Therapeutics?
- The average employee salary at Nucleome Therapeutics is approximately $123.7k per year.
- Analyze the salary distribution
- How many new job postings does Nucleome Therapeutics open per year?
- In Q1 2026, Nucleome Therapeutics opened 0 new job postings. In 2025, Nucleome Therapeutics opened 0 new job postings — about 0 per month.
- Track hiring trends by role
- When was Nucleome Therapeutics founded and where is it headquartered?
- Nucleome Therapeutics was founded in 2019 and is headquartered in Oxford, United Kingdom.
- Compare Nucleome Therapeutics to industry peers
Speak with a workforce expert about Nucleome Therapeutics.
Book a DemoSee something that doesn't look right? Reach out and our team will review it.